Zacks Investment Research downgraded shares of MEDIFAST INC (MED) from OUTPERFORM to NEUTRAL on October 19, 2012, with a target price of $31.60.
Medifast Inc has one operating subsidiary, Jason Pharmaceuticals, Inc, its manufacturing arm. They are engaged in the production, distribution, and sale of consumable health and diet products. Their product lines include weight management, meal replacement and sports nutrition products manufactured in a modern facility in Owings Mills, Maryland.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on MEDIFAST INC (MED),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment